✦ LIBER ✦

The gamma-secretase inhibitor BMS-708163 causes dose-dependent reductions in CSF Aβ40 levels in patients with mild-to-moderate Alzheimer's disease (AD)

✍ Scribed by Charles Albright; Niels Andreasen; Lennart Minthon; Kaj Blennow; Howard Feldman; Holly Soares; Flora Berisha; Paul Rhyne; Linda Rollin; Vlad Coric; Robert Berman

Book ID: 118467756
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 58 KB
Volume: 7
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2011.05.905

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cerebral microbleeds in a phase 2 clinic

Cerebral microbleeds in a phase 2 clinical trial of mild-to-moderate Alzheimer's disease with the gamma secretase inhibitor BMS-708163

✍ Feldman, Howard; Coric, Vlad; Sperling, Reisa; Greenberg, Steven; Bronen, Richar 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Three cases of apparent Vasogenic Edema

Three cases of apparent Vasogenic Edema (VE) from a phase 2 clinical trial of the gamma secretase Inhibitor BMS-708163 in patients with mild-to-moderate AD

✍ Sperling, Reisa; Bronen, Richard; Greenberg, Steven; Sorensen, A. Gregory; Sallo 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 52 KB